Association of the DDAH2 gene polymorphism with type 2 diabetes and hypertension

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 125-131

  Seo, Hyun Ae ^a   Kim, Su Won ^a   Jeon, Eon Ju ^a   Jeong, Ji Yun ^a   Moon, Seong Su ^b   Lee, Won Kee ^a   Kim, Jung Guk ^a   Lee, In Kyu ^a   Park, Keun Gyu ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

Author keywords

DDAH2; Hypertension; Polymorphism; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; TRIACYLGLYCEROL; UREA;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DDAH2 GENE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; KOREA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; WAIST CIRCUMFERENCE;

AMIDOHYDROLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; QUESTIONNAIRES; REPUBLIC OF KOREA;

EID: 84867397498     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.04.015     Document Type: Article

References (30)

1. Grossman E., Messerli F.H. Hypertension and diabetes. Adv Cardiol 2008, 45:82-106.
2. Shiekh G.A., Ayub T., Khan S.N., Dar R., Andrabi K.I. Reduced nitrate level in individuals with hypertension and diabetes. J Cardiovasc Dis Res 2011, 2:172-176.
3. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylargininedimethylaminohydrolase. Circulation 2002, 106:987-992.
4. Vincent M.A., Montagnani M., Quon M.J. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003, 3:279-288.
5. Han S.H., Quon M.J., Koh K.K. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007, 18:58-65.
6. Cooke J.P., Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997, 48:489-509.
7. Palmer R.M., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 1988, 333:664-666.
8. Vallance P., Leiper J. Blocking NO synthesis: how, where and why?. Nat Rev Drug Discov 2002, 1:939-950.
9. Murray-Rust J., Leiper J., McAlister M., Phelan J., Tilley S., Santa Maria J., et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylargininedimethylaminohydrolase. Nat Struct Biol 2001, 8:679-683.
10. Ogawa T., Kimoto M., Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylargininedimethylaminohydrolase, from rat kidney. J Biol Chem 1989, 264:10205-10209.
11. Böger R.H., Bode-Böger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
12. You L., Zhao C.X., Shao J.M., Zhang L., Wang D.W. Plasma asymmetric dimethylarginine and cystatin C levels in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi 2010, 38:798-800.
13. Głowińska-Olszewska B., Luczyński W., Jabłońska J., Otocka A., Florys B., Bossowski A. Asymmetric dimethylarginine (ADMA) in children with diabetes type 1. Pediatr Endocrinol Diabetes Metab 2010, 16:137-141.
14. Malecki M.T., Undas A., Cyganek K., Mirkiewicz-Sieradzka B., Wolkow P., Osmenda G., et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care 2007, 30:2899-2901.
15. Hanai K., Babazono T., Nyumura I., Toya K., Tanaka N., Tanaka M., et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009, 24:1884-1888.
16. Palm F., Onozato M.L., Luo Z., Wilcox C.S. Dimethylargininedimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007, 293:H3227-H3245.
17. Birdsey G.M., Leiper J.M., Vallance P. Intracellular localization of dimethylargininedimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand 2000, 168:73-79.
18. Nijveldt R.J., Teerlink T., Siroen M.P., van Lambalgen A.A., Rauwerda J.A., van Leeuwen P.A. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003, 22:17-22.
19. Tojo A., Welch W.J., Bremer V., Kimoto M., Kimura K., Omata M., et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997, 52:1593-1601.
20. Tran C.T., Fox M.F., Vallance P., Leiper J.M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 2000, 68:101-105.
21. Hu X., Atzler D., Xu X., Zhang P., Guo H., Lu Z., et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 2011, 31:1540-1546.
22. Wang D., Gill P.S., Chabrashvili T., Onozato M.L., Raggio J., Mendonca M., et al. Isoform-specific regulation by N(G),N(G)-dimethylargininedimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007, 101:627-635.
23. Hasegawa K., Wakino S., Tatematsu S., Yoshioka K., Homma K., Sugano N., et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice over expressing dimethylarginiedimethylaminohydrolase 2. Circ Res 2007, 101:e2-e10.
24. Gad M.Z., Hassanein S.I., Abdel-Maksoud S.M., Shaban G.M., Abou-Aisha K. Association of DDAH2 gene polymorphism with cardiovascular disease in Egyptian patients. J Genet 2011, 90:161-163.
25. Abhary S., Burdon K.P., Kuot A., Javadiyan S., Whiting M.J., Kasmeridis N., et al. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 2010, 5:e9462.
26. Maas R., Erdmann J., Lüneburg N., Stritzke J., Schwedhelm E., Meisinger C., et al. Polymorphisms in the promoter region of the dimethylargininedimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol Res 2009, 60:488-493.
27. Lu T.M., Lin S.J., Lin M.W., Hsu C.P., Chung M.Y. The association of dimethylargininedimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011, 10:16.
28. Ding H., Wu B., Wang H., Lu Z., Yan J., Wang X., et al. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ Res 2010, 106:1145-1152.
29. Hanchard N., Rockett K., Udalova I., Wilson J., Keating B., Koch O., et al. An investigation of transmission ratio distortion in the central region of the human MHC. Genes Immun 2006, 7(January (1)):51-58.
30. Cho Y.S., Chen C.H., Hu C., Long J., Ong R.T., Sim X., et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet 2011, 44:67-72.